Analysis of the 1,774 patients across 4 RCTs revealed that BRAF inhibitor increased the risk of developing all-grade and high-grade cuSCC in cancer patients with a RR of 4.72, 95% CI: 2.42–9.20, and RR of 4.92, 95% CI: 2.64–9.16, respectively (Figure 4), suggesting a nearly five-fold greater risk for developing cuSCC with single agent BRAF inhibitor versus dual BRAF/MEK inhibitors. This evidence concerns the gene MAP2K7 and cancer.